MedTrace Logo

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

NCT00338026 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2008-07-15

No results posted yet for this study

Summary

The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.

Conditions

Interventions

DRUG

ECO-4601

Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)

Sponsors & Collaborators

  • Thallion Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Petr Kavan, MD, Ph.D. · Sir Mortimer B. Davis - Jewish General Hospital

  • Benoît Samson, MD · Hopital Charles Lemoyne

  • Gerald Batist, MD · Sir Mortimer B. Davis - Jewish General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338026 on ClinicalTrials.gov